ライフサイエンスコーパス: treatment plan

1 should be carefully considered when making a treatment plan.

2 malignancy, with surgery being part of their treatment plan.

3 on the side of the prostate with a change in treatment plan.

4 ment plan, and milestones for evaluating the treatment plan.

5 dentifying underlying causes and tailoring a treatment plan.

6 ffer good care and patients to engage in the treatment plan.

7 ld be expected and factored into the overall treatment plan.

8 periodontists for this stage of the overall treatment plan.

9 However, reactivation can affect the cancer treatment plan.

10 heir expressed concern and their recommended treatment plan.

11 whether the results would modify the initial treatment plan.

12 therapy including an individualized surgical treatment plan.

13 and how CBCT influenced the diagnosis and/or treatment plan.

14 tates a specific and detailed assessment and treatment plan.

15 perative to ensure successful individualized treatment plans.

16 erences in symptom evaluation and developing treatment plans.

17 ose a concern for large-scale antiretroviral treatment plans.

18 n and its effects may be a target for future treatment plans.

19 eement between claims-inferred care and NOPR treatment plans.

20 itis, and consequently significantly affects treatment plans.

21 s may facilitate development of personalized treatment plans.

22 ortion of visits that resulted in error-free treatment plans.

23 and immature teratoma (IT) to assist future treatment plans.

24 eous implants is an integral facet of dental treatment plans.

25 with fibromyalgia and should be included in treatment plans.

26 evelopment of child-specific, evidence-based treatment plans.

27 mes compared to standard surgical or medical treatment plans.

28 ses and properly personalized prevention and treatment plans.

29 tient is crucial for developing personalized treatment plans.

30 unger, healthier populations when developing treatment plans.

31 undant systems and each may require specific treatment plans.

32 e level and add a developmental dimension to treatment plans.

33 ty, they have changed the way many cases are treatment planned.

34 ce-informed approach to case formulation and treatment planning.

35 e assessed for use of PET during staging and treatment planning.

36 omab radioimmunotherapy for potential use in treatment planning.

37 ace, the evaluation of their advancement and treatment planning.

38 ion and prognostic evaluation and can change treatment planning.

39 y indicating careful assessment and specific treatment planning.

40 ility or the characterization of lesions for treatment planning.

41 ntary tool for assessing ischemic damage and treatment planning.

42 or the diagnosis of hip abnormalities and in treatment planning.

43 , only clinical parameters are important for treatment planning.

44 pies for alcohol dependence is important for treatment planning.

45 it is unrecognized at the time of radiation treatment planning.

46 terest that may be relevant for radiotherapy treatment planning.

47 e tumor process with sufficient accuracy for treatment planning.

48 de invaluable tools for accurate staging and treatment planning.

49 ecise risk stratification and individualized treatment planning.

50 ith 74 Gy of TRT utilizing three-dimensional treatment planning.

51 troma is imperative for accurate staging and treatment planning.

52 ed beneficial in long-term tumor control and treatment planning.

53 this should be considered in prevention and treatment planning.

54 are, forming the basis of cancer staging and treatment planning.

55 prospective usefulness in cancer therapy and treatment planning.

56 ostatectomy or radiation therapy and salvage treatment planning.

57 ntal practice because it directly influences treatment planning.

58 ld be considered as early as possible during treatment planning.

59 on of lung nodules and consequently enhances treatment planning.

60 lowed by 4-dimensional (4D) CT for radiation treatment planning.

61 This may greatly improve preoperative treatment planning.

62 rease the accessibility of PET for radiation treatment planning.

63 nes on its necessity and use for periodontal treatment planning.

64 be used as a prognostic marker for tailored treatment planning.

65 ed variable for clinical staging and aphasia treatment planning.

66 tially useful information that may influence treatment planning.

67 T which would result in better diagnosis and treatment planning.

68 f thyroid cancer patients and individualized treatment planning.

69 analysis tool for orthodontic diagnosis and treatment planning.

70 from secretin-enhanced MR imaging for their treatment planning.

71 corneal thickness were taken into account in treatment planning.

72 nsidered to have a potential major impact on treatment planning.

73 renic nerve, all needed for PV cryoabalation treatment planning.

74 ies have an important place in diagnosis and treatment planning.

75 cations, diagnostic potential, and impact on treatment planning.

76 dicator of cancer stage and is important for treatment planning.

77 brachytherapy includes three components, (1) treatment planning, (2) placement of the sources and (3)

78 risk stratification is crucial for effective treatment planning after myocardial infarction (MI).

79 the tissue, which forms the basis of current treatment planning algorithms.

80 As part of standard treatment planning, all patients underwent SPECT imaging

81 After initial examination and treatment planning, all patients underwent the periodont

82 t model could be used as the backbone of the treatment planning, allowing optimization of the absorbe

83 activated sludge of a commercial wastewater treatment plan and identified as Gordonia species by 16S

84 ecific emergency medication and an emergency treatment plan and training in administration of emergen

85 nel had access to the latest developments in treatment planning and beam delivery and to all updated

86 on as well as information that is useful for treatment planning and cancer prevention.

87 er investigation to understand its impact on treatment planning and clinical trial design.

88 ubstantial technologic advances in radiation treatment planning and delivery have made possible exqui

89 radiation therapy represent new paradigms in treatment planning and dose delivery.

90 tandardize imaging terminology to facilitate treatment planning and enable precise comparison of resu

91 3D cancer cell culture models to improve IRE-treatment planning and facilitate widespread clinical us

92 cellent technology for patient selection and treatment planning and follow-up.

93 ar stage, the nomogram is expected to aid in treatment planning and future trial design.

94 margins have been reduced through the use of treatment planning and image-guidance technology.

95 rs deployed during focal therapies to inform treatment planning and in vivo monitoring in thin tissue

96 mation and selection of a treatment regimen; treatment planning and informed consent; ordering of tre

97 This technology may support novel treatment planning and monitoring approaches in oncology

98 Such an association may be of importance to treatment planning and outcome in these patients.

99 h as outcome assessment, neurocritical care, treatment planning and rapid, precision-diagnosis.

100 ation may be more favorable for the areas of treatment planning and response evaluation.

101 cancer and use of C stage for multimodality treatment planning and risk stratification in prospectiv

102 of implant-supported restorations; detailed treatment planning and sequence are presented.

103 Thus, detection of hypoxia can guide treatment planning and serve as a predictor of patient p

104 Challenges with IRE include complex treatment planning and the induction of intense muscle c

105 t of cancer, including screening, diagnosis, treatment planning and therapy monitoring.

106 on of extent of disease and may add value in treatment planning and treatment monitoring of high-grad

107 view current imaging modalities used in SBRT treatment planning and tumour assessment and review the

108 he use of imaging and image registration for treatment planning and verification, with emphasis on th

109 dence of mortality was 11.65% under observed treatment plans and 10.10% under the intervention, yield

110 2C); and addressing goals of care, including treatment plans and end-of-life planning (as appropriate

111 The results of PET/CT can alter treatment plans and have particular use in guiding site-

112 sting to its effects it is likely to improve treatment plans and prognosis.

113 address medical update, patient preferences, treatment plan, and milestones for evaluating the treatm

114 and treatment outcome assessment, 2) implant treatment planning, and 3) anatomic characterization.

115 sonance imaging (MRI) for target definition, treatment planning, and closed-loop control of energy de

116 niques plays an important role in diagnosis, treatment planning, and follow-up.

117 aging in prostate cancer detection, staging, treatment planning, and follow-up.

118 g their probable clinical course, facilitate treatment planning, and identify high-risk patients for

119 shed method increasingly used for diagnosis, treatment planning, and monitoring in gliomas.

120 in clinical practice for diagnosis, staging, treatment planning, and response assessment, the transit

121 inability of patients to follow through with treatment plans, and (c) emotional distress for patients

122 l trials; lower adherence to medications and treatment plans; and psychosocial stressors relevant to

123 A treatment planning approach to radionuclide therapy will

124 younger age, depression, and a complex drug treatment plan are associated with lower medication adhe

125 The optimal investigation and treatment plans are still controversial.

126 s and comorbidities, along with an optimized treatment plan, are the foundation for the proper intens

127 its are vital in making a decision about the treatment plan as it can persist one year or more follow

128 necrosis in tumors is of prognostic value in treatment planning, as necrosis is associated with aggre

129 areas of radiation oncology for imaging and treatment planning, as well as for radiosensitization to

130 of teeth planned for extraction as part of a treatment plan at initial examination.

131 f-life decisions with clinicians to create a treatment plan based on patient wishes.

132 s may lead to optimization of individualized treatment planning based on pretreatment imaging.

133 opments are likely to include individualized treatment plans based on patient-specific parameters inc

134 ls suggest the possibility of individualized treatment plans based on recovery potential.

135 the ways in which clinicians develop patient treatment plans based on the results of those trials.

136 The treating oncologist indicated a treatment plan before and after biopsy to determine whet

137 pleted questionnaires regarding the proposed treatment plan before and after functional MR imaging an

138 Treatment plans before and after functional MR imaging d

139 and substance use in patient assessments and treatment planning, both to prevent adverse transitions

140 t the point of referral, of which 29.8% were treatment planned by the periodontist for two or more ex

141 e profiles of biopsy tissues may help direct treatment plans by assessing prostate cancer pathologic

142 lth-risk behaviors and increase adherence to treatment plans by their patients.

143 patient participation in the decision of the treatment plan can be implemented.

144 he ocular surface, an accurate diagnosis and treatment plan can be made for patients presenting with

145 f complications make judgments about optimal treatment plans challenging.

146 linical features, and whether their previous treatment plan changed due to WES results.

147 to clinical and laboratory findings, cancer treatment plan (chemotherapy, radiotherapy, or surgery),

148 ajor clinical role in guiding diagnostic and treatment planning decisions in patients with mental dis

149 cancer therapy, radiation dosimetry supports treatment planning, dose-response analyses, predictions

150 ur could therefore play an important role in treatment planning, enabling treatment to be targeted in

151 lection of patients and for an adaptation of treatment planning, especially in selected patients (par

152 Because these findings might affect the treatment plan for childhood SRNS, it might be advisable

153 laying a definitive diagnosis or an adequate treatment plan for individual patients.

154 ans are an important component of a thorough treatment plan for minimizing risk to the IAN and optimi

155 echanical approach should be included in the treatment plan for patients with knee osteoarthritis.

156 atification for developing an individualized treatment plan for patients with thyroid cancer.

157 al activity is an essential component of any treatment plan for the patient with fibromyalgia.

158 on were completed in 7 weeks and changed the treatment plan for the patient.

159 st, a hindrance to selecting the appropriate treatment plan for, accurate genotype-phenotype correlat

160 Five patients with chronic periodontitis and treatment planned for a maxillary immediate denture were

161 Thirteen patients who had treatment planned for CTG on a single tooth were recruit

162 Teeth treatment planned for extraction were significant as a f

163 This study included four patients previously treatment planned for extractions of three or more anter

164 ologic dosimetry (3D-RD) was used for (131)I treatment planning for an 11-y-old girl with differentia

165 However, when treatment planning for an immediate implant in the poste

166 systems have created confusion about optimal treatment planning for AYAs, a population that spans the

167 cond, the flow models can be used to improve treatment planning for cardiovascular disease.

168 ently applied prognostic criteria for use in treatment planning for childhood ALL.

169 rin on BOP could impair proper diagnosis and treatment planning for clinicians and introduce a signif

170 omography (CBCT) for the diagnosis of and/or treatment planning for intrabony and furcation defects,

171 the use of CBCT for the diagnosis of and/or treatment planning for intrabony and furcation defects.

172 ing CBCT imaging for the diagnosis of and/or treatment planning for intrabony and/or furcation defect

173 ET with (18)F-FDG has been used in radiation treatment planning for non-small cell lung cancer (NSCLC

174 Treatment planning for patients with MDS who are HCT can

175 Treatment planning for persistent pain in later life req

176 Treatment planning for pregnant women with bipolar disor

177 cancer imaging that may improve staging and treatment planning for prostate cancer patients.

178 h can potentially enhance long-term care and treatment planning for psychiatric patients.

179 Such analyses are expected to be useful in treatment planning for radionuclide therapy.

180 mass and shows the value of this approach in treatment planning for RIT.

181 Radioiodine treatment planning for these patients is usually perform

182 abling more accurate diagnosis, staging, and treatment planning for these tumors.

183 possibility of real-time re-optimization of treatment plans for Adaptive Radiotherapy (ART).

184 effective and individualized pharmacological treatment plans for children with inflammatory bowel dis

185 s of word reading and can be used to develop treatment plans for individuals with reading disabilitie

186 These results warrant individualized treatment plans for patients with heterogeneous genetic

187 highlights key diagnostic tools and optimal treatment plans for SCFE.

188 ificantly more likely to develop appropriate treatment plans for standardized patients with contextua

189 [95% CI, 76%-86%]) or developing appropriate treatment plans for standardized patients with medical i

190 ng guideline-based therapies when developing treatment plans for teens with asthma.

191 Accordingly, to assist in designing treatment plans for therapeutic radiopharmaceuticals, an

192 f recent large clinical trials have modified treatment plans formerly based on inferred mechanisms of

193 We model the South African government's treatment plan from 2004-2008, and we predict the conseq

194 A treatment plan from the specialist should have clear dir

195 RIS was used to guide RT decision making and treatment planning; however, this advantage only reached

196 Optimal multidisciplinary treatment planning improves the outcome of each patient

197 Overall, PET/CT resulted in starting a new treatment plan in 70.8% of patients with positive residu

198 sing a desire for hastened death; document a treatment plan in diagnosed patients; and follow up resp

199 amily and child about the need for an asthma treatment plan in school and support the school nurse me

200 describe the approach used to determine the treatment plan in this young child.

201 iew of the impact of imaging in urolithiasis treatment planning in 2013.

202 A critical component of treatment planning in dental implant therapy is the amou

203 nd plays a definite role in diagnosis of and treatment planning in gallbladder polyps.

204 the crucial role of endoscopic ultrasound in treatment planning in patients with gastric mucosa-assoc

205 For optimal treatment planning in radionuclide therapy, robust tumor

206 cer treatment outcome, could greatly improve treatment planning in radiotherapy and chemotherapy.

207 w become routine in preoperative staging and treatment planning in the community and appears to be be

208 iable adjunctive tool for both diagnosis and treatment planning in the field of dentistry.

209 Patients need individualised approaches and treatment plans in view of the variations in tumour aggr

210 The complete treatment plan included neoadjuvant CRT (cisplatin + 5-f

211 DHD is likely better served with a mutimodal treatment plan, including medication, parent/school coun

212 f prostatic TCC enables accurate staging and treatment planning, including assessment of the risk of

213 Post-NaF PET treatment plans, including combinations of 2 modes of th

214 (SLND), a mainstay of melanoma diagnosis and treatment planning, increases the risk of in-transit met

215 te to use an evidenced-based approach when a treatment plan is being developed for bone augmentation

216 ient participation in the elaboration of the treatment plan is expected to substantially improve the

217 e disease score provides evidence that a new treatment plan is needed.

218 A multidimensional treatment plan is then formulated targeting the pain mec

219 ration of functional imaging techniques into treatment planning is another important step.

220 imetry becomes obvious when the objective of treatment planning is to achieve disease cures, safely,

221 The greatest challenge in treatment planning is to assign an accurate prognosis an

222 Formulation of policy and individual treatment plans is hampered by lack of data regarding th

223 rent standard practice for radioembolization treatment planning makes use of nuclear medicine imaging

224 ourse of SUD treatment outcomes and that SUD treatment planning may benefit from identifying and addr

225 These results showed that modification of treatment plans may be necessary when esthetics are crit

226 and clinicians using collaborative goals and treatment plans may overcome barriers to achieving hyper

227 east emphasis on chemotherapy in the overall treatment plan (mean [SEM] score, 2.60 [0.07]; P = .001)

228 60 total patients, 46 underwent the complete treatment plan (median age: 60.1 years; adenocarcinoma:

229 ion management techniques and psychiatrists' treatment plan modifications.

230 en utilization management and psychiatrists' treatment plan modifications.

231 therapies exist for hyperhidrosis, and each treatment plan must be evaluated on a patient-by-patient

232 could be advantageous in therapy selection, treatment planning, objective response monitoring and fo

233 This could be useful in the treatment plan of immediate loading cases.

234 e efficacy of incorporating IDM/HiDAC in the treatment plan of pediatric and adolescent patients with

235 nd established in the detection, staging and treatment planning of cervical cancer and for identifyin

236 coverage and the critical structures in the treatment planning of helical tomotherapy (TOMO), volume

237 luable tool in the diagnosis, follow-up, and treatment planning of neuroendocrine tumor (NET).

238 valuable role in the diagnosis, staging, and treatment planning of the disease.

239 evaluate diagnostic work-up, counseling, and treatment plans of the seizure team before and after fun

240 ce spacing) were acquired and (12)C ion beam treatment planning (optimal accelerator energies, beam p

241 icians (e.g., failure to specify end-of-life treatment plans or to secure an ICU bed prior to electiv

242 hemoglobin A1c target ranges, individualized treatment plans, outpatient pharmacologic treatment, glu

243 Before establishment of treatment plans, patients were administered a survey inc

244 ght be used in high-risk PC before radiation treatment planning, potentially affecting this planning

245 formation from (18)F-fluciclovine PET in the treatment-planning process led to significant difference

246 formation from (18)F-fluciclovine PET in the treatment-planning process led to significant difference

247 ilable treatment options integrated into the treatment plan properly.

248 Integrated revascularization treatment plans provide minimally invasive options for p

249 with a wide range of diagnoses and radiation treatment plans provided serum samples both before and d

250 he intervention with outcomes under observed treatment plans provides meaningful information about th

251 normal brain, while maintaining the similar treatment plan qualities on the thirteen patients treate

252 Controversy exists in treatment planning relative to the attempt of saving a t

253 evaluation, followed by a psychoeducational/treatment planning session.

254 As part of her multidisciplinary treatment plan, she consulted with two plastic surgeons

255 An individualised treatment plan should be devised depending on the clinic

256 Treatment planning should incorporate contributing facto

257 ith MLBO and if resection is not part of the treatment plan, stenting is safe and improves the effici

258 hese results begin to explain differences in treatment planning strategies between glass and resin ra

259 had a RIS and CT-scan correlation to aid in treatment planning (subgroup B1, n = 40) versus those wh

260 am arrangements and can be integrated in the treatment planning system for clinical application direc

261 In each case, the respective treatment-planning target volume expansion (PTV, PTV1, o

262 lovine in modifying the defined clinical and treatment-planning target volumes in postprostatectomy p

263 For each patient, the clinical and treatment-planning target volumes that would have been t

264 st as a core member of the multidisciplinary treatment planning team, it is crucial for imagers to re

265 sy, and offers a framework to develop a safe treatment plan that has the optimal outcome for the pati

266 pathogenic mechanisms, our report includes a treatment plan that prevents unnecessary discontinuation

267 We conclude that treatment plans that emphasize directly observed therapy

268 tients, and use their expertise to formulate treatment plans that reflect patient preferences and are

269 inicians should explain and advocate for the treatment plan they believe is appropriate.

270 ment strategy (ATS) is a rule for adapting a treatment plan to a patient's history of previous treatm

271 develop and implement a modeling method for treatment planning to determine the optimal combination

272 ntial to enable comprehensive evidence-based treatment plans to be implemented quickly, rather than i

273 d dermatologists, who provided diagnoses and treatment plans to primary care physicians (PCPs).

274 y risk under observed antiretroviral therapy treatment plans to the 5-year mortality risk that would

275 should be discussed and initiated with early treatment planning, to allow the best chance for future

276 rtant to accurately define tumor volumes for treatment planning, to determine the most aggressive tum

277 Treatment planning under International Society of Paedia

278 The secondary endpoints were changes in treatment plan, use of resources, and changes in disposi

279 tide and the activity should be optimized in treatment planning using the proposed method.

280 f extrahepatic deposition, and sometimes for treatment planning, using a partition model.

281 ffect of functional MR imaging on changes in treatment plan was assessed with the Wilcoxon signed ran

282 The initial treatment plan was based on the results from conventiona

283 In 40.9% of patients, the treatment plan was changed after the scans, owing mainly

284 In 17 patients, the treatment plan was changed and the new lesion was surgic

285 thorough oral and periodontal examination, a treatment plan was developed that included oral hygiene

286 In prostate FOM, the concordance across all treatment plans was lower if the patients had ADT claims

287 Clinical stage, risk assessment, and treatment plan were determined with and without the cont

288 idence ratings between altered and unaltered treatment plans were assessed with the Mann-Whitney U te

289 Three radiation treatment plans were designed for each patient.

290 Ten Gray treatment plans were repeatedly administered, using penc

291 Treatment plans were reviewed for quality assurance (QA)

292 Added value was determined by changes in treatment plan when (68)Ga-DOTATATE PET/CT results were

293 atomical imaging provides reference data for treatment planning, while real-time temperature monitori

294 rognosis and inheritance pattern, as well as treatment plans will in the future be based on genetic d

295 specific treatment arc, and (e) generates a treatment plan with the optimized angles.

296 patients underwent computed tomography-based treatment planning with pelvic regions and inguinal node

297 We compared organ-specific dosimetry for treatment planning with the whole-body dose-assessment m

298 anesthesiologist and surgeon to design their treatment plans with these limitations in mind.

299 uestionnaire before the scan to indicate the treatment plan without (68)Ga-PSMA-11 PET/CT information

300 onnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediate